306 related articles for article (PubMed ID: 23772627)
1. A global approach to HIV-1 vaccine development.
Stephenson KE; Barouch DH
Immunol Rev; 2013 Jul; 254(1):295-304. PubMed ID: 23772627
[TBL] [Abstract][Full Text] [Related]
2. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.
Kwong PD; Mascola JR; Nabel GJ
Cold Spring Harb Perspect Med; 2011 Sep; 1(1):a007278. PubMed ID: 22229123
[TBL] [Abstract][Full Text] [Related]
3. Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine.
Schwerdtfeger M; Andersson AC; Neukirch L; Holst PJ
J Transl Med; 2019 May; 17(1):175. PubMed ID: 31126293
[TBL] [Abstract][Full Text] [Related]
4. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
[TBL] [Abstract][Full Text] [Related]
5. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
[TBL] [Abstract][Full Text] [Related]
6. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
7. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
Asbach B; Kibler KV; Köstler J; Perdiguero B; Yates NL; Stanfield-Oakley S; Tomaras GD; Kao SF; Foulds KE; Roederer M; Seaman MS; Montefiori DC; Parks R; Ferrari G; Forthal DN; Phogat S; Tartaglia J; Barnett SW; Self SG; Gottardo R; Cristillo AD; Weiss DE; Galmin L; Ding S; Heeney JL; Esteban M; Jacobs BL; Pantaleo G; Wagner R
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429343
[TBL] [Abstract][Full Text] [Related]
8. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
[TBL] [Abstract][Full Text] [Related]
9. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
[TBL] [Abstract][Full Text] [Related]
10. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus.
van Diepen MT; Chapman R; Douglass N; Galant S; Moore PL; Margolin E; Ximba P; Morris L; Rybicki EP; Williamson AL
J Virol; 2019 Apr; 93(8):. PubMed ID: 30760570
[TBL] [Abstract][Full Text] [Related]
11. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
Sadanand S; Suscovich TJ; Alter G
Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
[TBL] [Abstract][Full Text] [Related]
12. Intrastructural help: improving the HIV-1 envelope antibody response induced by virus-like particle vaccines.
Temchura V; Überla K
Curr Opin HIV AIDS; 2017 May; 12(3):272-277. PubMed ID: 28422791
[TBL] [Abstract][Full Text] [Related]
13. Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.
Page M; Stebbings R; Berry N; Hull R; Ferguson D; Davis L; Duffy L; Elsley W; Hall J; Ham C; Hassall M; Li B; Mee ET; Quartey-Papafio R; Rose NJ; Mathy N; Voss G; Stott EJ; Almond N
Retrovirology; 2012 Jul; 9():56. PubMed ID: 22799593
[TBL] [Abstract][Full Text] [Related]
14. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.
Karlsson Hedestam GB; Fouchier RA; Phogat S; Burton DR; Sodroski J; Wyatt RT
Nat Rev Microbiol; 2008 Feb; 6(2):143-55. PubMed ID: 18197170
[TBL] [Abstract][Full Text] [Related]
15. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
[TBL] [Abstract][Full Text] [Related]
16. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
van Gils MJ; Sanders RW
Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
[TBL] [Abstract][Full Text] [Related]
17. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning.
Kwong PD; Mascola JR; Nabel GJ
Nat Rev Immunol; 2013 Sep; 13(9):693-701. PubMed ID: 23969737
[TBL] [Abstract][Full Text] [Related]
18. Toward an antibody-based HIV-1 vaccine.
Hoxie JA
Annu Rev Med; 2010; 61():135-52. PubMed ID: 19824826
[TBL] [Abstract][Full Text] [Related]
19. The design and evaluation of HIV-1 vaccines.
Saunders KO; Rudicell RS; Nabel GJ
AIDS; 2012 Jun; 26(10):1293-302. PubMed ID: 22706011
[TBL] [Abstract][Full Text] [Related]
20. Prospects for a globally effective HIV-1 vaccine.
Excler JL; Robb ML; Kim JH
Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]